3 days ago · But kidney cancer is a disease with fewer mutations, and therefore fewer targets to manufacture the vaccine. It was important for the investigators to learn as much as possible from this early phase study about how the vaccine influences an immune response to the tumor.

2 days ago · In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.The patients had a form of kidney cancer called clear cell renal cell carcinoma and were deemed at high risk for recurrence due to the advanced stage of the ...

3 days ago · All nine patients with advanced kidney cancer in an early-phase trial of a personalized therapeutic vaccine had successful anti-cancer immune responses and remained cancer-free approximately three years after treatment. A therapeutic vaccine is used after disease sets in, aiming to induce immunity to alter the course of disease. Each patient’s vaccine was created with information found by ...

1 day ago · A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

2 days ago · THURSDAY, Feb. 6, 2025 (HealthDay News) -- A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors, explained a team led by Dr ...

2 days ago · A personalized cancer vaccine (PCV) to target neoantigens (mutant proteins expressed only by cancer cells) was delivered to individuals with stage III–IV kidney cancer (renal cell carcinoma; RCC ...

Several newer immunotherapies, in particular PD-1/PD-L1 and CTLA-4 checkpoint inhibitors, have become an integral part of the management of advanced or metastatic kidney cancer. There are currently seven FDA-approved immunotherapy options for kidney cancer either as a single agent or in combination with another immunotherapy or targeted therapy.

Researchers want to see how well a personalized vaccine works for people with kidney cancer when given with pembrolizumab immunotherapy. The people in this study have renal cell carcinoma that was or will be removed with surgery.

2 days ago · Nine patients with advanced kidney cancer who received an experimental vaccine tailored to their tumors’ specific mutations mounted an immune response to their disease and remained cancer-free ...

THURSDAY, Feb. 6, 2025 -- A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors, explained a team led by Dr. David Braun of the ...